Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Pharmacia & Upjohn

Executive Summary

Pharmacia & Upjohn: Delarvirdine expanded access program for non-nucleoside reverse transcriptase inhibitor for HIV infection has begun, firm announces. The expanded access program is open to HIV-1 positive patients 13 and older with CD4 counts below 300. The patients must be failing other therapies and receiving at least one other antiretroviral agent. An NDA for accelerated approval of Rescriptor is planned for "the next few months," Pharmacia & Upjohn said...
Advertisement
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS027960

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel